AbbVie 2013 Annual Report Download - page 73

Download and view the complete annual report

Please find page 73 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Foreign Currency Translation
Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets
of foreign subsidiaries are translated into U.S. dollars using period end exchange rates. The U.S. dollar
effects that arise from translating the net assets of these subsidiaries at changing rates are recognized in
other comprehensive income (OCI). The net assets of subsidiaries in highly inflationary economies are
remeasured as if the functional currency were the reporting currency. The remeasurement is recognized
in earnings and is immaterial for all years presented.
Derivatives
All derivative instruments are recognized as either assets or liabilities at fair value in AbbVie’s balance
sheets and are classified as current or long-term based on the scheduled maturity of the instrument.
The accounting for changes in the fair value of a derivative instrument depends on whether it has been
formally designated and qualifies as part of a hedging relationship under the applicable accounting
standards and, further, on the type of hedging relationship.
For derivatives formally designated as hedges, the company assesses at inception and quarterly
thereafter, whether the hedging derivatives are highly effective in offsetting changes in the fair value or
cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value
hedge and of the hedged item attributable to the hedge risk are recognized in earnings immediately.
Fair value hedges are used to hedge the interest rate risk associated with certain of the company’s
fixed-rate debt. The effective portions of changes in the fair value of a derivative designated as a cash
flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the
underlying hedged item. Cash flow hedges are used to manage exposures from changes in foreign
currency exchange rates.
The derivatives that are not designated and do not qualify as hedges are adjusted to fair value through
current earnings. If it is determined that a derivative is no longer highly effective as a hedge, the
company discontinues hedge accounting prospectively. Gains or losses are immediately reclassified from
AOCI to earnings relating to hedged forecasted transactions that are no longer probable of occurring.
Gains or losses relating to terminations of effective cash flow hedges in which the forecasted
transactions are still probable of occurring are deferred and recognized consistent with the income or
loss recognition of the underlying hedged items. Terminations of a fair value hedge result in fair value
adjustments to the hedged items until the date of termination with the new bases being accreted to par
value on the date of maturity.
Derivatives, including those that are not designated as a hedge, are principally classified in the operating
section of the consolidated statements of cash flows, consistent with the underlying hedged item.
Refer to Note 9 for information regarding AbbVie’s derivative and hedging activities.
Note 3 Supplemental Financial Information
Interest Expense (Income), Net
years ended December 31 (in millions) 2013 2012 2011
Interest expense $299 $104 $ —
Interest and dividend income (21) (20) (20)
Interest expense (income), net $278 $ 84 $(20)
69